LONDON, July 3, 2026, 17:08 BST
- Haleon closed at 364.30p, up 1.08%, ahead of a 0.25% rise for the FTSE 100.
- The stock rose 4.6% from June 26; Friday volume was 13.0 million shares, about half its 26.38 million average.
- Haleon said about 86% of its £500 million 2026 buyback had been completed by June 18.
- July 30 H1 results will test whether Q1’s negative volume/mix can move toward the 3%-5% organic sales guide.
Haleon PLC (LON:HLN) rose for a third straight session at the London close on Friday. The Sensodyne maker has gained 4.8% since Tuesday’s close, a small but notable rebound before half-year results later this month, with the share count and cost story doing more work than sales momentum.
The stock closed at 364.30p, up 1.08%, versus a 0.25% gain for the FTSE 100. The close was still 12.45% below Haleon’s 52-week high of 416.10p set on Feb. 18. Friday volume was 13.0 million shares, about 49% of the 26.38 million average shown by Investors Chronicle.
| Latest tape | Haleon | FTSE 100 |
|---|---|---|
| Friday close | 364.30p | 10,679.03 |
| Friday change | +1.08% | +0.25% |
| Thursday change | +2.82% | +1.67% |
| June 26-July 3 change | +4.6% | +1.6% |
The buyback is the cleanest support in the near term. Haleon said shares with voting rights stood at 8,808,899,708 at June 30, with 12,006,714 held in treasury. At Friday’s close, that voting-share base implies equity value of about £32.1 billion, making the full £500 million 2026 buyback equal to about 1.6% of equity value.
Haleon’s June 29 H1 aide memoire said about 86% of the 2026 buyback had been completed by June 18, or about £430 million on a simple reading of the £500 million plan. It also put the expected H1 diluted share count at about 8.9 billion.
Microsoft Corp NASDAQ:MSFT is the other fresh part of the story, though the July 1 announcement gave no financial terms. Haleon said the five-year deal would use Azure, Copilot and AI agents across consumer insights, R&D, supply chain and commercial execution. Claire Dickson, Haleon’s chief digital and technology officer, called it a “major step forward”. Darren Hardman, Microsoft UK and Ireland CEO, said Haleon was moving with “real pace and purpose”. Business Wire
| Q1 scorecard | Reported revenue | Organic growth |
|---|---|---|
| Group | £2.86 bln | +2.2% |
| Oral Health | £932 mln | +8.3% |
| Vitamins, minerals and supplements | £414 mln | +1.7% |
| Pain Relief | £654 mln | -0.3% |
| Respiratory Health | £499 mln | -3.4% |
| North America | £932 mln | +1.0% |
The operating base is still mixed. Haleon’s Q1 organic growth of 2.2% was carried by price, up 2.4%, while volume/mix fell 0.2%. North America grew 1.0% organically, but its volume/mix was down 2.7%, which keeps the July 30 print focused on real demand rather than pricing.
CEO Brian McNamara said in April that Haleon remained “on track to deliver” its full-year guidance. In February, he told Reuters the U.S. “will grow this year”; Chris Beckett, an analyst at Quilter Cheviot, said U.S. households felt “financially stretched”. Haleon’s 2026 organic revenue guide is 3%-5%, below its 4%-6% medium-term range. Haleon Corporate
The Thorne process ties back to that same growth gap. Reuters reported on June 26 that Haleon had bid for private U.S. supplements firm Thorne, which the Financial Times said could be valued at up to $4 billion; Haleon said it did not comment on “rumour or speculation”. In Q1, vitamins, minerals and supplements made up 14.5% of Haleon revenue and grew 1.7%, while Oral Health made up 32.6% and grew 8.3%, calculations from Haleon’s figures show. Reuters
Haleon lists H1 2026 results for July 30. That report will put numbers next to the share-count benefit, North America’s shelf reset claims and whether volume/mix has started to recover after the first-quarter decline.
